SUBSTITUTED AMINOTHIAZOLES AS INHIBITORS OF CANCERS, INCLUDING HEPATOCELLULAR CARCINOMA, AND AS INHIBITORS OF HEPATITIS VIRUS REPLICATION
Pharmaceutical compositions of the invention are presented which comprise substituted aminothiazoles derivatives. The substituted aminothiazoles derivatives have a disease-modifying action in the treatment of diseases associated with unregulated cell growth. Such diseases include cancers such as hepatocellular carcinoma, and viral infections from a hepatitis virus.
1 . A compound having formula (I):
Including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, wherein:
R 1 is selected from the group consisting of hydrogen, C 1 -C 9 linear alkyl, isopropyl, cyclohexyl, bromine, cyano,
R 2 is selected from the group consisting of hydrogen, methyl, isopropyl, tert-butyl, benzyl, and
Ar 1 is selected from the group consisting of phenyl,
Ar 2 is selected from the group consisting of phenyl,
wherein compounds of the structures
are excluded from the compounds of formula (I).
2 . (canceled)
3 . (canceled)
4 . (canceled)
5 . (canceled)
6 . The compound according to claim 1 , which is:
4-(pyridin-2-yl)-n-(pyrimidin-4-yl)thiazol-2-amine;
4-(6-bromopyridin-2-yl)-n-(pyrimidin-2-yl)thiazol-2-amine;
4-(4-methylpyridin-2-yl)-n-(pyrimidin-2-yl)thiazol-2-amine;
4-(3,5-dimethylpyridin-2-yl)-n-(pyrimidin-2-yl)thiazol-2-amine;
6-(2-(pyrimidin-2-ylamino)thiazol-4-yl)pyridin-2-ol;
N-(pyrimidin-2-yl)-4-(quinolin-2-yl)thiazol-2-amine;
N-(5-chloropyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;
N-(5-bromopyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;
N-(4-methylpyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine:
4-(pyridin-2-yl)-N-(4-(trifluoromethyl)pyrimidin-2-yl)thiazol-2-amine;
6-methyl-N-(4-(pyridin-2-yl)thiazol-2-yl)benzo[d]thiazol- 2 -amine;
5-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-ethyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-pentyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-cyclohexyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-nonyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N-benzyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
2-((4-(pyridin-2-yl)thiazol-2-yl)(pyrimidin-2-yl)amino)ethanol;
5-bromo-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methanol;
(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl acetate;
(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl butyrate;
Ethyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
Ethyl 4-(4-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate ;
ethyl 4-(6-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate ;
ethyl 2-((4-methylpyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5-carboxylate ;
4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylic acid;
methyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
tert-butyl 2-(tert-butyl(pyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5-carboxylate;
4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;
N-methyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide
N-benzyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;
24-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino) benzamido)-1,21-dioxo-1-(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)-5,8,11,14,17-pentaoxa-2,20-diazapentacosan-25-oic acid;
N-(31-oxo-35-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-3, 6, 9, 12, 15, 18, 21, 24, 27-nonaoxa-30-azapentatriacontyl)-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino) thiazole-5-carboxamide;
4-Pyridin-2-yl-2-(pyrimidin-2-ylamino)-thiazole-5-carbonitrile;
and pharmaceutically acceptable forms thereof.
7 . A composition comprising an effective amount of at least one compound according to claim 1 .
8 . A composition according to claim 7 , further comprising at least one excipient.
9 . A composition according to claim 8 , wherein the at least one compound is at least one member selected from the group consisting of:
4-(pyridin-2-yl)-N-(pyrimidin-4-yl)thiazol-2-amine;
4-(6-bromopyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
4-(4-methylpyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
4-(3,5-dimethylpyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
6-(2-(pyrimidin-2-ylamino)thiazol-4-yl)pyridin-2-ol;
N-(pyrimidin-2-yl)-4-(quinolin-2-yl)thiazol-2-amine;
N-(5-chloropyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;
N-(5-bromopyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;
N-(4-methylpyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine:
4-(pyridin-2-yl)-N-(4-(trifluoromethyl)pyrimidin-2-yl)thiazol-2-amine;
6-methyl-N-(4-(pyridin-2-yl)thiazol-2-yl)benzo[d]thiazol-2-amine;
5-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-ethyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-pentyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-cyclohexyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-nonyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N-benzyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
2-((4-(pyridin-2-yl)thiazol-2-yl)(pyrimidin-2-yl)amino)ethanol;
5-bromo-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methanol;
(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl acetate;
(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl butyrate;
Ethyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
Ethyl 4-(4-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
Ethyl 4-(6-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
Ethyl 2-((4-methylpyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5 -carboxylate;
4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylic acid;
Methyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
tert-butyl 2-(tert-butyl(pyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5-carboxylate;
4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;
N-methyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;
N-benzyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;
24-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)-1,21-dioxo-1-(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)-5,8,11,14,17-pentaoxa-2,20-diazapentacosan-25-oic acid;
N-(31-oxo-35-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3, 4-d]imidazol-4-yl)-3, 6, 9, 12, 15, 18, 21, 24, 27-nonaoxa-30-azapentatriacontyl)-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino) thiazole-5-carboxamide;
4-Pyridin-2-yl-2-(pyrimidin-2-ylamino)-thiazole-5-carbonitrile and pharmaceutically acceptable forms thereof.
10 . (canceled)
11 . A method for treating a disease associated with unregulated cell growth, said method comprising administering to a subject an effective amount of at least one compound of the formula (I),
including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, to treat the disease wherein:
R 1 is selected from the group consisting of hydrogen, C 1 -C 9 linear alkyl, isopropyl, cyclohexyl, bromine, cyano,
R 2 is selected from the group consisting of hydrogen, methyl, isopropyl, tert-butyl, benzyl, and
Ar 1 is selected from the group consisting of phenyl,
Ar 2 is selected from the group consisting of phenyl,
12 . (canceled)
13 . The method of claim 11 , wherein the at least one compound is administered in a composition further comprising at least one excipient.
14 . The method of claim 13 , wherein the at least one compound is at least one member selected from the group consisting of
4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N,4-diphenylthiazol-2-amine;
N-phenyl-4-(pyridin-2-yl)thiazol-2-amine;
4-phenyl-N-(pyrimidin-2-yl)thiazol-2-amine;
N,4-di(pyridin-2-yl)thiazol-2-amine;
4-(pyridin-3-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
4-(pyridin-4-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N-(pyrazin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;
4-(pyridin-2-yl)-N-(pyrimidin-4-yl)thiazol-2-amine;
4-(6-bromopyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
4-(4-methylpyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
4-(3,5-dimethylpyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
6-(2-(pyrimidin-2-ylamino)thiazol-4-yl)pyridin-2-ol;
N-(pyrimidin-2-yl)-4-(quinolin-2-yl)thiazol-2-amine;
N-(5-chloropyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;
N-(5-bromopyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;
N-(4-methylpyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine:
4-(pyridin-2-yl)-N-(4-(trifluoromethyl)pyrimidin-2-yl)thiazol-2-amine;
6-methyl-N-(4-(pyridin-2-yl)thiazol-2-yl)benzo[d]thiazol- 2 -amine;
5-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-ethyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-pentyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-cyclohexyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-nonyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N-benzyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
2-((4-(pyridin-2-yl)thiazol-2-yl)(pyrimidin-2-yl)amino)ethanol;
5-bromo-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methanol;
(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl acetate;
(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl butyrate;
Ethyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
Ethyl 4-(4-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
Ethyl 4-(6-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
Ethyl 2-((4-methylpyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5-carboxylate;
4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylic acid;
Methyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
tert-butyl 2-(tert-butyl(pyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5-carboxylate;
4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;
N-methyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;
N-benzyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;
24-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino)benzamido)-1,21-dioxo-1-(4- (pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)-5,8,11,14,17-pentaoxa-2,20- diazapentacosan-25-oic acid;
N-(31-oxo-35-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3, 4-d]imidazol-4-yl)-3, 6, 9, 12, 15, 18, 21, 24, 27-nonaoxa-30-azapentatriacontyl)-4-(pyridin-2-yl)-2-(pyrimidin-2- ylamino) thiazole-5-carboxamide;
4-Pyridin-2-yl-2-(pyrimidin-2-ylamino)-thiazole-5-carbonitrile;
3-(4-Phenyl-thiazol-2-ylamino)-phenol;
(3-Chloro-2-methyl-phenyl)-(4-pyridin-2-yl-thiazol-2-yl)-amine;
and pharmaceutically acceptable forms thereof.
15 . The method of claim 11 , wherein the disease associated with unregulated cell growth is a cancer selected from the group consisting of hepatocellular carcinoma, primary liver cancer, hepatoblastoma, breast cancer, ovarian cancer, lung cancer, leukemia and cholangiocarcinoma.
16 . (canceled)
17 . (canceled)
18 . (canceled)
19 . (canceled)
20 . (canceled)
21 . (canceled)
22 . (canceled)
23 . (canceled)
24 . The method of claim 11 , wherein the disease associated with unregulated cell growth is metastatic disease.
25 . A method for treating a disease associated with infection of the liver with a virus, said method comprising administering to a subject an effective amount of at least one compound of the formula (I),
including hydrates, solvates, pharmaceutically acceptable salts, prodrugs and complexes thereof, to treat the disease wherein:
R 1 is selected from the group consisting of hydrogen, C 1 -C 9 linear alkyl, isopropyl, cyclohexyl, bromine, cyano,
R 2 is selected from the group consisting of hydrogen, methyl, isopropyl, tert-butyl, benzyl, and
Ar 1 is selected from the group consisting of phenyl,
Ar 2 is selected from the group consisting of phenyl,
26 . (canceled)
27 . The method of claim 25 , wherein the at least one compound is administered in a composition further comprising at least one excipient.
28 . The method of claim 27 , wherein the at least one compound is at least one member selected from the group consisting of
4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N,4-diphenylthiazol-2-amine;
N-phenyl-4-(pyridin-2-yl)thiazol-2-amine;
4-phenyl-N-(pyrimidin-2-yl)thiazol-2-amine;
N,4-di(pyridin-2-yl)thiazol-2-amine;
4-(pyridin-3-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
4-(pyridin-4-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N-(pyrazin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;
4-(pyridin-2-yl)-N-(pyrimidin-4-yl)thiazol-2-amine;
4-(6-bromopyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
4-(4-methylpyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
4-(3,5-dimethylpyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
6-(2-(pyrimidin-2-ylamino)thiazol-4-yl)pyridin-2-ol;
N-(pyrimidin-2-yl)-4-(quinolin-2-yl)thiazol-2-amine;
N-(5-chloropyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;
N-(5-bromopyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine;
N-(4-methylpyrimidin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine:
4-(pyridin-2-yl)-N-(4-(trifluoromethyl)pyrimidin-2-yl)thiazol-2-amine;
6-methyl-N-(4-(pyridin-2-yl)thiazol-2-yl)benzo[d]thiazol-2-amine;
5-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-ethyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-pentyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-cyclohexyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
5-nonyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N-isopropyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N-methyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
N-benzyl-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
2-((4-(pyridin-2-yl)thiazol-2-yl)(pyrimidin-2-yl)amino)ethanol;
5-bromo-4-(pyridin-2-yl)-N-(pyrimidin-2-yl)thiazol-2-amine;
(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methanol;
(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl acetate;
(4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)methyl butyrate;
Ethyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
Ethyl 4-(4-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
Ethyl 4-(6-methylpyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
Ethyl 2-((4-methylpyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5 -carboxylate;
4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylic acid;
Methyl 4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxylate;
tert-butyl 2-(tert-butyl(pyrimidin-2-yl)amino)-4-(pyridin-2-yl)thiazole-5-carboxylate;
4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;
N-methyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;
N-benzyl-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazole-5-carboxamide;
24-(4-(((2,4-diaminopteridin-6-yl)methyl)(methyl)amino) benzamido)-1,21-dioxo-1-(4- (pyridin-2-yl)-2-(pyrimidin-2-ylamino)thiazol-5-yl)-5,8,11,14,17-pentaoxa-2,20-diazapentacosan-25-oic acid;
N-(31-oxo-35-((3as,4s,6aR)-2-oxohexahydro-1H-thieno[3, 4-d]imidazol-4-yl)-3, 6, 9, 12, 15, 18, 21, 24, 27-nonaoxa-30-azapentatriacontyl)-4-(pyridin-2-yl)-2-(pyrimidin-2-ylamino) thiazole-5-carboxamide;
4-pyridin-2-yl-2-(pyrimidin-2-ylamino)-thiazole-5-carbonitrile;
3-(4-phenyl-thiazol-2-ylamino)-phenol;
(3-chloro-2-methyl-phenyl)-(4-pyridin-2-yl-thiazol-2-yl)-amine;
and pharmaceutically acceptable forms thereof.
29 . The method of claim 25 , wherein the virus is a hepatitis virus.
30 . The method of claim 25 , wherein the hepatitis virus is the hepatits A virus.
31 . The method of claim 25 , wherein the hepatitis virus is the hepatits B virus.
32 . The method of claim 25 , wherein the hepatitis virus is the hepatits C virus.
33 . The method of claim 25 , wherein the hepatitis virus is the hepatits D virus.
34 . The method of claim 25 , wherein the hepatitis virus is the hepatits E virus.
35 . The method of claim 25 , wherein the virus is any virus infecting the liver